开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Brent Hodgkinson, Tianjiao Wang, Joshua Byrnes and Paul Scuffham
Background:
VZV is a vaccine preventable disease that has yet to be universally included in many countries vaccination schedules due to uncertainty over the cost-effectiveness of the vaccination strategies. Here we describe the results of a recently published systematic review of the literature that was conducted to summarise available evidence on the cost-effectiveness of VZV vaccination strategies.
Methods:
The systematic review was conducted in accordance with PRISMA guidelines and Cochrane methods.
Results:
Six cost-utility studies, all using dynamic transmission modelling (DTM) techniques were identified. All studies modelled a rapid decrease in VZV incidence following VZV vaccination and an increase in HZ incidence that could last for decades when exogenous boosting (EB) was assumed. The cost-effectiveness of VZV vaccination compared to no-vaccination ranged from being dominated when HZ increases lasted for >50 years to cost-effective ($7,000 to $61,000 in 2019 USD) and even dominant as the period where HZ incidence was elevated became shorter.
Conclusions:
The DTM models identified in the review are sensitive to EB assumptions and limited by requirements for homogeneity in infection risk within age groups. The use of agent-based models to account for the individual nature of infectiousness should be considered. Early work using an agent-based model has supported the results of DTM models identified in the original review.